Genetic Diversity: Driving cancer evolution

Tumor-growth-factor-beta signaling helps cancer cells to evolve and become resistant to drugs by down-regulating accurate DNA repair.
  1. Devon M Fitzgerald
  2. Susan M Rosenberg  Is a corresponding author
  1. Baylor College of Medicine, United States

Tumors can form when cells acquire mutations that allow them to grow and divide rapidly. Further mutations and the selection of successful cell clones allow the tumor to evolve and drive the progression of the disease with deadly consequences (reviewed by Gerlinger et al., 2014). Many tumors have unstable genomes with lots of small mutations and/or genome rearrangements, and this makes it more likely that the cancer will become progressively worse and evolve resistance to chemotherapy drugs (reviewed by Lee et al., 2016).

Historically, mutations were assumed to arise randomly, at constant rates. More recent discoveries indicate that cells and organisms can increase the rate at which they acquire new mutations (a process known as mutagenesis) when they activate cellular stress responses – that is, when they are stressed and poorly adapted to their environments (reviewed by Fitzgerald et al., 2017). Mutagenesis induced by stress has been predicted to speed up evolution (Ram and Hadany, 2012).

A signaling pathway known as tumor growth factor (TGF)-beta signaling promotes cell growth and is often up-regulated in cancer cells. Now, in eLife, Raffaella Sordella of Cold Spring Harbor Laboratory and colleagues – including Debjani Pal as first author – report that TGF-beta signaling in cancer cells temporarily down-regulates high-fidelity DNA repair, leading to populations of cells that are genetically diverse (Pal et al., 2017). These populations harbor more cells that are resistant to a broad range of chemotherapy drugs.

Pal et al. focused on a subpopulation of cells known as CD44+/CD24− cells, which arise randomly within many types of tumor and in cancer cell lines (reviewed by Polyak and Weinberg, 2009). They behave like stem cells thanks to the TGF-beta signaling pathway being continuously active, and are linked to drug-resistance, metastasis and other poor outcomes for patients (Shipitsin et al., 2007).

Cells generally use a process called homology-directed repair to mend double-stranded breaks in DNA. This process is mostly accurate and can heal DNA breaks without rearranging the chromosome. Pal et al. found that RNAs that encode proteins used in homology-directed repair and other types of DNA repair are less abundant in CD44+/CD24− cells. In these cells, DNA damage accumulates and genome re-arrangements occur, with the cells appearing to repair DNA breaks by other, less accurate, means.

TGF-beta signaling was necessary for homology-directed repair to be reduced in CD44+/CD24− cells, and sufficient for it to be reduced in other types of cells. Sequencing the genomes of individual cells demonstrated that TGF-beta signaling induces copy-number alterations – that is, insertions or deletions of gene-fragments to many neighboring genes – causing heritable genetic changes and populations of cells to become genetically diverse. Furthermore, Pal et al. used various cancer cell lines, primary tumor samples and published cancer genome datasets to demonstrate that TGF-beta signaling often decreases accurate DNA repair in cancer cells, which can cause copy-number alterations (Figure 1).

TGF-beta signaling promotes a form of DNA repair that accelerates cancer evolution.

Cells generally repair spontaneous DNA breaks by a process called homology-directed (HD) repair (left). TGF-beta signaling down-regulates this process, which leads to the DNA breaks being repaired by other, less accurate, forms of repair that destabilize chromosomes and generate large DNA deletions and duplications known as copy-number alterations (CNAs). This leads to populations of cells that are genetically diverse (middle). Subpopulations of cancer cells known as CD44+/CD24− cells often have over-active TGF-beta signaling: this leads these cells to acquire high levels of CNAs and to rapidly evolve resistance to chemotherapy. Treating other cells with TGF-beta has a similar effect. Cells with red nuclei have undergone genetic changes; the other colors represent the resulting diverse cell characteristics.

A gene called PMS1 – which operates in another DNA repair process called mismatch-repair – was also less active in CD44+/CD24− cells. Mismatch repair corrects small errors in DNA replication, and more mutations accumulate when it is down-regulated (reviewed by Scanlon and Glazer, 2015; Fitzgerald et al., 2017). Although Pal et al. did not examine whether small mutations are increased, we suspect that, like copy-number alterations, TGF-beta may have increased the production of small mutations as well.

Does the genome instability caused by TGF-beta signaling drive the evolution of cancers? Pal et al. used a clever model of short-term exposure to TGF-beta to show that the heritable genomic changes that occurred, not the TGF-beta signaling itself, help the cancer cells to adapt. Cell populations previously exposed to TGF-beta harbored more cells that were resistant to three chemotherapy drugs than populations that had not been exposed. Although Pal et al. did not test the tendency of these cells to become more dangerous, the increased adaptability of cells exposed to TGF-beta probably speeds the progression of cancer as well (Figure 1).

The consequences are important. We previously suggested that a new class of “anti-evolvability” drugs should be developed to target the processes of cancer evolution, rather than targeting the products of evolution (that is, the disease characteristics; Rosenberg and Queitsch, 2014). Current anti-cancer drugs act to reduce the ability of cancer cells to grow and divide, and some induce mutagenesis (Fitzgerald et al., 2017). Inhibiting evolution itself might reduce the emergence of drug resistance.

Several stress-related proteins that promote mutagenesis and other mechanisms that change cell characteristics are promising targets for these new drugs (Rosenberg and Queitsch, 2014; Fitzgerald et al., 2017). The findings of Pal et al. suggest that proteins of the TGF-beta signaling pathway are potential targets for new “anti-evolvability” drugs that could be effective against many different types of cancer. Several drugs that target the TGF-beta pathway are already in clinical trials (reviewed by Herbertz et al., 2015).

This study also suggests the possibility that organisms may increase mutagenesis and evolution in the normal course of development. Programmed mutagenesis and evolution drive our adaptive immune systems, but might also underlie other complex developmental programs that require more flexibility and responsiveness than our genomes encode (discussed by Fitzgerald et al., 2017; Pal et al., 2017). TGF-beta signaling controls how wounds heal, certain aspects of embryo development, and how the nervous system forms. Future work may indicate that TGF-beta and other inducible mutagenesis responses allow multicellular complexity and flexibility in ways not yet appreciated.

References

Article and author information

Author details

  1. Devon M Fitzgerald

    1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
    2. Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States
    3. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, United States
    4. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2480-7269
  2. Susan M Rosenberg

    1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
    2. Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States
    3. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, United States
    4. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, United States
    For correspondence
    smr@bcm.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1444-473X

Publication history

  1. Version of Record published: March 10, 2017 (version 1)

Copyright

© 2017, Fitzgerald et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,368
    Page views
  • 413
    Downloads
  • 4
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Devon M Fitzgerald
  2. Susan M Rosenberg
(2017)
Genetic Diversity: Driving cancer evolution
eLife 6:e25431.
https://doi.org/10.7554/eLife.25431

Further reading

    1. Cancer Biology
    Wanyoung Lim, Inwoo Hwang ... Sungsu Park
    Research Article

    Chemoresistance is a major cause of treatment failure in many cancers. However, the life cycle of cancer cells as they respond to and survive environmental and therapeutic stress is understudied. In this study, we utilized a microfluidic device to induce the development of doxorubicin-resistant (DOXR) cells from triple negative breast cancer (TNBC) cells within 11 days by generating gradients of DOX and medium. In vivo chemoresistant xenograft models, an unbiased genome-wide transcriptome analysis, and a patient data/tissue analysis all showed that chemoresistance arose from failed epigenetic control of the nuclear protein-1 (NUPR1)/histone deacetylase 11 (HDAC11) axis, and high NUPR1 expression correlated with poor clinical outcomes. These results suggest that the chip can rapidly induce resistant cells that increase tumor heterogeneity and chemoresistance, highlighting the need for further studies on the epigenetic control of the NUPR1/HDAC11 axis in TNBC.

    1. Cancer Biology
    2. Computational and Systems Biology
    Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
    Research Article

    Non-invasive early cancer diagnosis remains challenging due to the low sensitivity and specificity of current diagnostic approaches. Exosomes are membrane-bound nanovesicles secreted by all cells that contain DNA, RNA, and proteins that are representative of the parent cells. This property, along with the abundance of exosomes in biological fluids makes them compelling candidates as biomarkers. However, a rapid and flexible exosome-based diagnostic method to distinguish human cancers across cancer types in diverse biological fluids is yet to be defined. Here, we describe a novel machine learning-based computational method to distinguish cancers using a panel of proteins associated with exosomes. Employing datasets of exosome proteins from human cell lines, tissue, plasma, serum, and urine samples from a variety of cancers, we identify Clathrin Heavy Chain (CLTC), Ezrin, (EZR), Talin-1 (TLN1), Adenylyl cyclase-associated protein 1 (CAP1), and Moesin (MSN) as highly abundant universal biomarkers for exosomes and define three panels of pan-cancer exosome proteins that distinguish cancer exosomes from other exosomes and aid in classifying cancer subtypes employing random forest models. All the models using proteins from plasma, serum, or urine-derived exosomes yield AUROC scores higher than 0.91 and demonstrate superior performance compared to Support Vector Machine, K Nearest Neighbor Classifier and Gaussian Naive Bayes. This study provides a reliable protein biomarker signature associated with cancer exosomes with scalable machine learning capability for a sensitive and specific non-invasive method of cancer diagnosis.